Business Wire

VALAMIS

22.7.2021 10:02:14 CEST | Business Wire | Press release

Share
Valamis Announces Acquisition of The Working Manager to Redefine Internal Career Development

Valamis , the global leader in digital learning technologies and workforce development, has announced the acquisition of The Working Manager (TWM), a leader in organisational performance and career mobility technology. Valamis and TWM have entered into a definitive agreement to join together and unify technologies and in-house consulting services to offer businesses an end-to-end employee experience that helps employees develop and find career opportunities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005023/en/

Valamis Learning Solution and TWM’s CareerBurst career platform and learning platform technologies will bring Executives, Human Resources, Learning & Development, and Talent professionals a technology and consulting solution to develop and retain employees for organisational performance. Valamis and TWM will be able to help over 3 million learners and serve a diverse global client base.

“The Working Manager’s technology, proven record of customer satisfaction, and most importantly their people, are a complete fit with Valamis’ longstanding values. With TWM’s internal career development platform, LMS, and LXP, we will enhance our current learning solutions for our customers and future customers. Together, our technology, partnership approach, and authenticity will give the market a solution that puts people first and helps customers every step of the way succeed with their business initiatives”, explained Jussi Hurskainen, CEO, Valamis.

After a long period of remote work for many employees across the world at the onset of the pandemic, many businesses have begun outlining their ‘return to the office’ plans, which has ushered in what NPR is calling the ‘Great Resignation’, as more workers in the U.S. are quitting their jobs than at any time in at least two decades. According to a LinkedIn report , 94% of employees would stay at a company longer if it invested in their careers. The acquisition and combined products and services of Valamis and TWM will provide an opportunity for employers to reduce the high cost of employee turnover and labour shortages by upskilling their employees and improving career mobility.

“At TWM our accounts managers are all former heads of L&D, we understand first-hand many of the challenges that our customers are facing. That helps us develop our software in line with those requirements but also gives us an understanding of the partnership that is required to address the rapidly changing needs of businesses. Valamis has a similar approach and company culture that will empower businesses across the U.K. and globally to build greater employee loyalty and, in the end – stronger businesses”, said Phil Purver, CEO, TWM.

About Valamis

Valamis is an international technology company specialising in cloud-based digital learning solutions that empower millions of learners, companies, and societies to solve their challenges with transformative learning experiences. Valamis’ end-to-end learning solution includes Valamis’ LXP, LMS, LRS, Content Authoring Lesson Studio, eCommerce, and extensive integrations. Valamis creates long-term value for businesses and their people by being a strategic partner in learning while providing technology and consultancy services in design, data science, technology, corporate performance, and digital learning. Founded in 2003, Valamis is headquartered in Finland and maintains offices in countries around the world.

Learn more about Valamis: Website | YouTube | LinkedIn | Twitter

About TWM

TWM is the most reputable provider of Learning Platforms for clients who have a strategic take on developing their people. Our difference is that our people are former L&D professionals. We always work closely and in partnership with clients, helping solve their problems and providing a platform that we guarantee will do what we say it will.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye